Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system
PLOS One · 2025
DOI: 10.1371/journal.pone.0333130 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Lingling Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai' an), Huaian, Jiangsu Province, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Product Surveillance, Postmarketing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Pharmaceutical Association.
Abstract (Originalsprache)
Purpose
Excessive daytime sleepiness (EDS) seriously affects quality of life and may increase the risk of life-threatening situations, such as motor vehicle accidents. Solriamfetol is a novel medication approved for the treatment of EDS and serves as an alternative to traditional stimulants. This retrospective pharmacovigilance study aimed to analyze adverse events (AEs) related to solriamfetol based on real-world data.
Methods
Data regarding solriamfetol-related adverse events were retrieved from the FDA Adverse Event Reporting System (FAERS) from Q3 of 2019 to Q1 of 2024. A total of 1550 reports on solriamfetol-related AEs were analyzed using disproportionality analysis to identify AE signals across various organ systems.
Results
A large proportion of AEs were reported among female patients (64.06%), primarily including those with narcolepsy (38.13%) and obstructive sleep apnea (3.68%). The most frequently reported AEs included headache, anxiety, and drug ineffectiveness, with 46.8% of AEs occurring within 7 days of treatment initiation. Furthermore, solriamfetol was significantly associated with psychiatric and nervous system disorders as well as cardiac and general disorders.
Conclusions
Solriamfetol-related adverse events were mainly psychiatric, neurological, cardiac, and general disorders, with headache, anxiety, and drug ineffectiveness being the most common. Nearly half of the events occurred within the first week of treatment. Given the limitations of the FAERS database, further prospective studies are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pharmacy, Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai' an), Huaian, Jiangsu Province, China.
- Department of Pharmacy, Yangzhou University Huai'an Medical Collaborative Innovation Center, Huaian, Jiangsu Province, China.
ORCID-Profile: Kaijian Zhu
Förderung
- Jiangsu Pharmaceutical Association
Zitieren
APA
Wu, L., & Zhu, K. (2025). Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system. PLOS One. https://doi.org/10.1371/journal.pone.0333130
Vancouver
Wu L, Zhu K. Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system. PLOS One. 2025. doi:10.1371/journal.pone.0333130
BibTeX
@article{Wu2025,
author = {Wu, Lingling and Zhu, Kaijian},
title = {Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0333130}
}
EUVIMED